professor Sarah Wordsworth
Colleges
Sarah Wordsworth
BSc MSc PhD
Professor of Health Economics
I joined the Health Economics Research Centre in January 2003 and developed a research programme on the economics of genetic and genomic technologies. Of particular interest are the economics of translating high-throughput sequencing technologies such as whole genome sequencing in rare diseases and cancer into health care systems.
My other research interests include antimicrobial resistance (AMR) where I explore the contribution that health economics can bring to this important health area and identify barriers to implementing interventions for reducing AMR. I also address methodological challenges in trial based economic evaluations in the areas of surgery for obesity, lung cancer surgery, cardiovascular disease and eye disease.
I undertake policy work and lead the Health Economics Genomics England Clinical Interpretation Partnership (GeCIP). for the UK’s 100,000 Genomes Project. This is the largest sequencing initiative in the world, and sequenced 100,000 entire genomes from around 70,000 National Health Service patients with rare diseases and cancer.
As a Senior Fellow at St. Anne’s College I am a member of the college Governing Body, graduate advisor for DPhil and MSc students and part of the Centre for Personalised Medicine (St. Anne’s and Wellcome Trust Centre for Human Genetics).
I teach a variety of undergraduate and graduate students, I am also Co-Director of the MSc in Precision Cancer Medicine (University of Oxford) and supervise DPhil students.
I worked in the Health Economics Research Unit at the University of Aberdeen from 1995-2002, after completing my MSc in Health Economics in 1995 at the University of York.
Recent publications
-
Cost-effectiveness of genetic-based screening strategies for maturity-onset diabetes of the young.
Journal article
Kovács G. et al, (2023), Per Med
-
Lessons learned from the application of the HEcoPerMed guidance to three modeling case studies.
Journal article
Nagy B. et al, (2023), Per Med
-
Cost-effectiveness of extended DPYD testing before fluoropyrimidine chemotherapy in metastatic breast cancer in the UK.
Journal article
Koleva-Kolarova R. et al, (2023), Per Med
-
Cost–effectiveness and budget impact analysis of screening strategies for maturity-onset diabetes of the young in three European countries
Journal article
Szilberhorn L. et al, (2023), Personalized Medicine
-
Financial incentives to promote personalized medicine in Europe: an overview and guidance for implementation
Journal article
Koleva-Kolarova R. et al, (2023), Personalized Medicine